Related Experiment Video
Updated: Jan 4, 2026
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts
Leonid Visochek1, Dikla Atias2, Itay Spektor2
1Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
Abstract:
Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80-90%) of PANC1 cancer cells in xenografts, measured 30 days after the treatment with PJ34 has been terminated. Benign cells infiltrated into the PANC1 tumors (stroma) were not affected. Growth, weight gain and behavior of the treated nude mice were not impaired during, and 30 days after the treatment with PJ34. The efficient eradication of malignant cells in human pancreas cancer xenografts presents a new model of pancreas cancer treatment.
Insights
The novel compound PJ34 effectively eradicated human pancreatic cancer cells in xenografts by disrupting mitosis. This targeted approach significantly reduced tumors without harming benign cells or affecting mouse health, offering a promising new cancer treatment model.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Modified phenanthridine PJ34 has shown efficacy in eradicating various human cancer cells.
- PJ34's mechanism involves preventing NuMA clustering in mitotic spindle poles, crucial for normal mitosis in malignant cells.
Purpose of the Study:
- To investigate the effect of PJ34 on human pancreas ductal adenocarcinoma cell cultures and xenografts.
- To evaluate PJ34 as a potential treatment for pancreatic cancer.
Main Methods:
- Testing PJ34 in cell cultures and xenografts of human pancreatic cancer (PANC1 cells).
- Assessing cancer cell reduction and impact on benign stromal cells.
- Monitoring the health and behavior of treated nude mice.
Main Results:
- Substantial reduction (80-90%) of PANC1 cancer cells observed in xenografts 30 days post-treatment.
- Benign stromal cells within the tumors remained unaffected by PJ34.
- No adverse effects on the growth, weight, or behavior of treated nude mice were noted.
Conclusions:
- PJ34 demonstrates significant efficacy in eradicating human pancreatic cancer cells in vivo.
- The compound selectively targets malignant cells, sparing benign stromal cells.
- PJ34 represents a potential new therapeutic model for pancreatic cancer treatment with minimal systemic toxicity.
